The technology has been a core capability of the firm, which is expanding its suite of products to address the broader needs of genomics researchers.
The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.
IDT has licensed the CRISPR/Cpf1 RNA-guided editing system from the Broad Institute and intends to sell it to pharmaceutical and other commercial labs.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The acquisition of San Diego-based ValueGene expands IDT's presence in Southern California.
The companies will combine their respective technologies and expertise to develop new products for low-input, targeted RNA-seq applications.
As the interference proceeding to resolve claims in foundational CRISPR patents draws near, Caribou has given IDT worldwide rights to sell RUO reagents.
The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.
IDT said that the acquisition is expected to expand the customer base for its custom synthetic nucleic acid business across Southeast Asia.
The new 8,000-square-foot building will support oligonucleotide manufacturing for molecular biology applications such as qPCR, next-generation sequencing, and synthetic biology.
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.
Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.
Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.
In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.